1. Home
  2. HPQ vs VTRS Comparison

HPQ vs VTRS Comparison

Compare HPQ & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HP Inc.

HPQ

HP Inc.

HOLD

Current Price

$19.04

Market Cap

17.3B

Sector

Technology

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$13.94

Market Cap

17.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HPQ
VTRS
Founded
1939
1961
Country
United States
United States
Employees
N/A
30000
Industry
Computer Manufacturing
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.3B
17.2B
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
HPQ
VTRS
Price
$19.04
$13.94
Analyst Decision
Hold
Buy
Analyst Count
12
4
Target Price
$21.42
$13.50
AVG Volume (30 Days)
17.6M
7.5M
Earning Date
05-27-2026
05-07-2026
Dividend Yield
6.24%
3.47%
EPS Growth
N/A
N/A
EPS
0.58
N/A
Revenue
$55,295,000,000.00
$14,299,900,000.00
Revenue This Year
$3.10
$4.41
Revenue Next Year
$0.39
$1.96
P/E Ratio
$33.16
N/A
Revenue Growth
3.24
N/A
52 Week Low
$17.56
$7.34
52 Week High
$29.55
$16.47

Technical Indicators

Market Signals
Indicator
HPQ
VTRS
Relative Strength Index (RSI) 50.40 52.82
Support Level $17.96 $12.90
Resistance Level $20.09 $16.38
Average True Range (ATR) 0.77 0.31
MACD 0.01 0.10
Stochastic Oscillator 42.18 88.00

Price Performance

Historical Comparison
HPQ
VTRS

About HPQ HP Inc.

HP (formerly Hewlett-Packard) is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise. HP focuses on the commercial market, but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one third of sales coming from the US. HP completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: